First Trust Advisors’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.17M | Buy |
68,470
+30,157
| +79% | +$822K | ﹤0.01% | 1875 |
|
|
2025
Q4 | $1.04M | Buy |
38,313
+2,782
| +8% | +$73.3K | ﹤0.01% | 2125 |
|
|
2025
Q3 | $919K | Buy |
+35,531
| New | +$823K | ﹤0.01% | 2119 |
|
|
2025
Q1 | – | Sell |
-18,372
| Closed | -$464K | – | 2549 |
|
|
2024
Q4 | $464K | Sell |
18,372
-19,071
| -51% | -$518K | ﹤0.01% | 2274 |
|
|
2024
Q3 | $1.27M | Sell |
37,443
-40,293
| -52% | -$1.54M | ﹤0.01% | 1943 |
|
|
2024
Q2 | $2.88M | Buy |
77,736
+7,841
| +11% | +$296K | ﹤0.01% | 1538 |
|
|
2024
Q1 | $2.93M | Buy |
69,895
+58,332
| +504% | +$2.4M | ﹤0.01% | 1565 |
|
|
2023
Q4 | $459K | Buy |
+11,563
| New | +$340K | ﹤0.01% | 2160 |
|
|
2023
Q2 | – | Sell |
-53,072
| Closed | -$1.91M | – | 2361 |
|
|
2023
Q1 | $1.91M | Buy |
+53,072
| New | +$2.29M | ﹤0.01% | 1701 |
|
|
2022
Q4 | – | Sell |
-10,399
| Closed | -$292K | – | 2443 |
|
|
2022
Q3 | $292K | Buy |
10,399
+440
| +4% | +$13.5K | ﹤0.01% | 2331 |
|
|
2022
Q2 | $268K | Sell |
9,959
-42,814
| -81% | -$1.24M | ﹤0.01% | 2327 |
|
|
2022
Q1 | $1.8M | Sell |
52,773
-49,010
| -48% | -$1.57M | ﹤0.01% | 1813 |
|
|
2021
Q4 | $3.93M | Buy |
+101,783
| New | +$4.44M | ﹤0.01% | 1486 |
|
|
2016
Q2 | – | Sell |
-182,343
| Closed | -$10.3M | – | 2297 |
|
|
2016
Q1 | $10.3M | Sell |
182,343
-312,618
| -63% | -$35.2M | 0.03% | 643 |
|
|
2015
Q4 | $116M | Buy |
494,961
+174,302
| +54% | +$38M | 0.3% | 61 |
|
|
2015
Q3 | $50.7M | Buy |
320,659
+31,167
| +11% | +$8.82M | 0.15% | 145 |
|
|
2015
Q2 | $110M | Sell |
289,492
-26,304
| -8% | -$10.4M | 0.28% | 76 |
|
|
2015
Q1 | $132M | Buy |
+315,796
| New | +$113M | 0.39% | 36 |
|
Other funds holding CLDX
KCM
VCM
CC
EP